The Pfizer logo is displayed on the exterior of a former Pfizer factory, on May 4, 2014, in the Brooklyn borough of New York. Pfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic. Both companies' boards have approved the deal, which still needs regulatory approval and approval from GBT shareholders. (AP Photo/Mark Lennihan, File)
August 8, 2022
Stories this photo appears in:
August 8, 2022 10:35 a.m.
Pfizer buying spree continues with $5.4B hematology deal
Pfizer Inc.'s vaccine and treatment brought in more than $16 billion combined just in the recently completed second quarter.